Currus Biologics
Melbourne, Australia· Est.
Australian biotech using a bispecific engager platform to unlock CAR‑T efficacy against solid tumours.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $20M
AI Company Overview
Australian biotech using a bispecific engager platform to unlock CAR‑T efficacy against solid tumours.
OncologyImmunology
Technology Platform
BEAT (Bispecific Engagers of Antigen Presenting Cells and T cells) is a bispecific antibody that links CAR‑T/TCR cells to professional APCs in lymph nodes, enhancing T‑cell expansion, licensing and tumour infiltration.
Opportunities
Successful IND filing and early‑phase data could unlock partnerships with major pharma seeking solid‑tumour immunotherapy platforms.
Risk Factors
Technical risk of translating pre‑clinical efficacy to humans, and funding risk if early clinical results are not compelling.
Competitive Landscape
Currus competes with other CAR‑T solid‑tumour developers (e.g., Autolus, Fate Therapeutics) but differentiates through its bispecific engager approach that leverages APC‑mediated T‑cell licensing.